Director/PDMR Shareholding

RNS Number : 8083A
Hikma Pharmaceuticals Plc
25 March 2013
 



 

Hikma Pharmaceuticals PLC - Vesting of 2010 LTIP

 

LONDON, 25 March 2013: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received conditional share awards which vested on 23 March 2013 under the 2005 Long Term Incentive Plan ("LTIP") and were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil. The persons concerned have retained all the shares exercised.

 

In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.

 

Bassam Kanaan

 

Vesting of LTIP 2010

49,476

(0.02% ISC)

25 March 2013

£10.24

Nil

468,134

(0.24% ISC)

Michael Raya

 

Vesting of LTIP 2010

44,384

(0.02% ISC)

25 March 2013

£10.24

Nil

56,584

(0.03% ISC)

Riad Mishlawi

Vesting of LTIP 2010

17,660

(0.01% ISC)

 

25 March 2013

£10.24

Nil

60,260

(0.03% ISC)

Khalid Nabilsi

Vesting of LTIP 2010

23,063

(0.01% ISC)

 

25 March 2013

£10.24

Nil

219,847

(0.11% ISC)



 

- ENDS -

 

Enquiries                                                                                                                                      

Peter Speirs                                                                          +44 20 7399 2760

Company Secretary, Hikma Pharmaceuticals PLC

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBSGDXGSDBGXU
UK 100

Latest directors dealings